

## Rebates and National Procurement Pricing Agreements 2023

The Pharmacy & Medicines Optimization Team (PMOT) of the Hertfordshire and West Essex Integrated Care Board (HWE ICB) considers offers of rebates on primary care prescribing costs in line with Appendix A.

The rebates in place across HWE ICB are listed below and are published on the website. They will only be collected in the place-based areas where the products are recommended on the place-based formulary. Where this differs between areas this is stated below.

Company	Product	PrescQIPP Approved?	Current Agreement Start Date	Current Agreement End Date
Chiesi	Clenil Modulite Beclometasone Dipropionate Inhaler (200 dose units) 50mcg/100mcg/200mcg/250mcg	Grey	01.07.2022	30.06.2024
Chiesi	Fostair pMDI Beclometasone dipropionate/formoterol fumarate dihydrate 100/6 – 200/6- pressurised metered dose inhaler 120 doses	Grey	01.07.2022	30.06.2024
NHSEI on behalf of Daiichi-Sankyo, Bayer and BMS	Lixiana - Edoxaban 15mg, 30mg & 60mg tablets Xarelto-Rivaroxaban Tablets 2.5mg, 10mg, 15mg & 20mg Eliquis- Apixaban 2.5mg & 5mg tablets	PrescQIPP state their assessment tool is not applicable to this scheme	01-01-2022	31-12-2025
Abbott	Freestyle Libre device	Not reviewed as Abbott did not submit it to PrescQIPP	1-4-2023	31-3-2025
Nestle	Resource thicken up clear (Herts only, not formulary in W Essex)	Not reviewed as Nestle did not submit it to PrescQIPP	1-4-2023	n/a

### Management of Rebates and National Pricing Agreements

Rebates and national pricing agreements are considered and agreed by the Senior Pharmacy & Medicines Optimisation Team (PMOT) within HWE ICB and signed off by the ICB Chief Finance Officer (CFO). When operational management of the rebates involves regular data processing by the PMOT, the time commitment to run data is balanced against any savings due to be made from the rebate. The management of data and respective payments due for the national pricing agreements are managed by National Health Service England and National Health Service Improvement (NHSEI).

## **Appendix A: NHS Herts and West Essex Integrated Care Board Primary Care Prescribing Pricing Agreement Process**

The HWE ICB pricing agreement list is reviewed regularly, ratified and the update re-published on the website if there are changes.

HWE ICB PMOT will only consider rebates on formulary medicines and prefer rebates which are approved by PrescQIPP. The PrescQIPP documentation can be found at:

<https://www.prescqipp.info/our-resources/webkits/primary-care-rebates/> (need to register and login to access).

PrescQIPP is a national organisation hosted and funded by the NHS to support quality prescribing in the NHS. PrescQIPP undertake a financial and clinical review of the offer and assist commissioners in managing the legal implications of entering into the presented schemes.

The PrescQIPP board gives an Assessment; **Red, Amber, or Grey** status depending on the outcome of the assessment stage. Classification is as follows:

**Grey** – Scheme Considered; No significant reservations

**Amber** – Scheme Considered; Not fully appropriate

**Red** – Scheme Considered; Not Appropriate

**National Pricing Agreements** are negotiated, offered, and managed by NHSEI.

### ***Local ICB Process:***

Only formulary agents will be considered for rebates or National Pricing Agreements.

The PrescQIPP evaluation of rebates is considered and discussed by a Senior Pharmacist within PMOT using the consideration list below. If assessed, only schemes classified as 'grey' or 'amber' will be considered by PMOT. If PrescQIPP assess as 'amber' and highlight issues which can be managed locally by HWE ICB.

- e.g.
- legal clauses which HWE ICB senior PMOT staff understand, and feel are low risk
  - provision of price together with quantity prescribed – where local assessment differs from PrescQIPP (e.g. due to preferred local use leading to high value of savings)
  - short term 1 or 2 years provided product in current use and on formulary

then these rebates will be carefully considered by PMOT independently.

If we accept a rebate that is not yet assessed by PrescQIPP we inform them that it exists and review the scheme when they classify it.

The CFO will individually 'sign-off' all agreements on behalf of HWE ICB.

The summary of rebates collected is documented and reviewed by the appropriate medicines committee of the HWE ICB.

**For a rebate to be considered by PMOT the following conditions need to be met:**

- 1.** The proposed scheme does not require a change in an existing clinical pathway (e.g., NICE/ local guidance/ best practice) or to medication use.
- 2.** The medicine or medical device for which the pricing agreement concerns is currently agreed by the Hertfordshire and West Essex Area Prescribing Committee (HWE APC) for prescribing in primary care or was previously approved by HWE APC previous equivalent committees across the area i.e., Hertfordshire Medicines Management Committee (HMMC) or West Essex Medicines Optimisation Programme Board (WE MOPB).
- 3.** The proposed medicine or medical device is being recommended within its product licence.
- 4.** The proposed scheme does not include an exclusivity clause that would restrict the individual prescriber’s clinical freedom.
- 5.** The anticipated net rewards through the proposed scheme are of sufficient value to warrant engagement. This value is defined locally.
- 6.** The collection of the saving is simple to administer.
- 7.** The length of the proposed scheme should be at least one year for HWE ICB to realise potential savings.
- 8.** Engaging with the proposed pricing agreement should not encourage prescribing contrary to HWE ICB prescribing policies.
- 9.** The integrity of HWE ICB should not be compromised in any way by engaging in the proposed pricing agreement scheme.
- 10.** The Freedom of Information (FOI) clause in the agreement must not restrict compliance of HWE ICB with its FOI obligations. Ideally ‘redacted’ agreements will be supplied by the manufacturer and held by HWE ICB staff to facilitate response to FOIs.

<b>Version</b>	2.0
<b>Developed by</b>	Sarah Crotty, HWE PMOT (With thanks to Derbyshire CCG and North Kirklees CCG)
<b>Date ratified</b>	May 2023 HWE ICS Medicines Optimisation meeting (MODIG) and subsequent Primary Care Commissioning Committee
<b>Review date</b>	May 2026